Christopher Alba, Shelly Malhotra, Stephanie Horsfall, Matthew E Barnhart, Adrie Bekker, Katerina Chapman, Coleen K Cunningham, Patricia E Fast, Genevieve G Fouda, Kenneth A Freedberg, Ameena Goga, Lusine R Ghazaryan, Valériane Leroy, Carlyn Mann, Margaret M McCluskey, Elizabeth J McFarland, Vincent Muturi-Kioi, Sallie R Permar, Roger Shapiro, Devin Sok, Lynda Stranix-Chibanda, Milton C Weinstein, Andrea L Ciaranello, Caitlin M Dugdale
INTRODUCTION: Approximately 130 000 infants acquire HIV annually despite global maternal antiretroviral therapy scale-up. We evaluated the potential clinical impact and cost-effectiveness of offering long-acting, anti-HIV broadly neutralizing antibody (bNAb) prophylaxis to infants in three distinct settings. METHODS: We simulated infants in Côte d'Ivoire, South Africa, and Zimbabwe using the Cost-Effectiveness of Preventing AIDS Complications-Pediatric (CEPAC-P) model...
November 7, 2023: medRxiv